Search research articles
Contact Us
Filters
Showing results (1071-1080 of 1,482) with videos related to
Page
of 149
Sort By:
Cancer
|
April 29, 2021
Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Koji Sasaki, et al.
American Journal of Hematology
|
May 18, 2022
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia
Courtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Blood
|
March 15, 2014
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms
Sa A Wang, Robert P Hasserjian, Patricia S Fox, et al.
Nature
|
October 31, 2024
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
Junya Sango, Saul Carcamo, Maria Sirenko, et al.
American Journal of Hematology
|
February 12, 2024
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia
Keith W Pratz, Brian A Jonas, Vinod Pullarkat, et al.
The Lancet. Microbe
|
March 10, 2024
Performance of a stool-based quantitative PCR assay for the diagnosis of tuberculosis in adolescents and adults: a multinational, prospective diagnostic accuracy study
Alexander Kay, Anca Vasiliu, Lucia Carratala-Castro, et al.
British Journal of Haematology
|
March 26, 2019
A Toll-like receptor 2 genetic variant modulates occurrence of bacterial infections in patients with sickle cell disease
Karina Tozatto-Maio, Robert Girot, Indou D Ly, et al.
Cancer
|
May 6, 2026
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy
Jennifer Marvin-Peek, Courtney D DiNardo, Sanam Loghavi, et al.
American Journal of Hematology
|
September 2, 2022
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Blood Cancer Discovery
|
March 8, 2021
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors
Ahmad S Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, et al.
Page
of 149
Search research articles
Search
Showing results (1071-1080 of 1,482) with videos related to
Sort By:
Page
of 149
Cancer
|
April 29, 2021
Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Koji Sasaki, et al.
American Journal of Hematology
|
May 18, 2022
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia
Courtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Blood
|
March 15, 2014
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms
Sa A Wang, Robert P Hasserjian, Patricia S Fox, et al.
Nature
|
October 31, 2024
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
Junya Sango, Saul Carcamo, Maria Sirenko, et al.
American Journal of Hematology
|
February 12, 2024
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia
Keith W Pratz, Brian A Jonas, Vinod Pullarkat, et al.
The Lancet. Microbe
|
March 10, 2024
Performance of a stool-based quantitative PCR assay for the diagnosis of tuberculosis in adolescents and adults: a multinational, prospective diagnostic accuracy study
Alexander Kay, Anca Vasiliu, Lucia Carratala-Castro, et al.
British Journal of Haematology
|
March 26, 2019
A Toll-like receptor 2 genetic variant modulates occurrence of bacterial infections in patients with sickle cell disease
Karina Tozatto-Maio, Robert Girot, Indou D Ly, et al.
Cancer
|
May 6, 2026
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy
Jennifer Marvin-Peek, Courtney D DiNardo, Sanam Loghavi, et al.
American Journal of Hematology
|
September 2, 2022
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Blood Cancer Discovery
|
March 8, 2021
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors
Ahmad S Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, et al.
Page
of 149